Graziella Pinto

Graziella Pinto

Auto-generated profile, based on publicly available information

Graziella Pinto

Pediatric Endocrinology Department, Necker-Enfants Malades University Hospital, AP-HP, Paris-Centre University , Paris

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
LBLaura G González Briceño
Laura G González Briceño
MVMagali Viaud
Magali Viaud
JBJacques Beltrand
Jacques Beltrand
IFIsabelle Flechtner
Isabelle Flechtner
YDYamina Dassa
Yamina Dassa
MPMichel Polak
Michel Polak
Objective Short stature in children and adolescents may lead to social and emotional stress with negative effects on quality of life (QoL). Growth hormone (GH) treatment may improve QoL through height normalisation. Our objective here was to evaluate general and height-specific QoL after one year of GH treatment. Design Prospective, single-centre, observational cohort study. Methods Children ≥4 years of age starting GH at our centre in 2012-2015 to treat short stature were studied. Patients with serious diseases, syndromic short stature, or developmental delay were excluded. At treatment initiation and 1 year later, patients and their parents completed the general PedsQL 4.0 and height-specific Quality of Life in Short Stature Youth (QoLiSSY) questionnaires. Correlations between self-report and parent-report scores and between height gain and QoL improvements were assessed based on Pearson’s correlation coefficients. Results 74 children (42 boys, 32 girls) aged 10.2±3 years (range: 4.1-16.6 years) were included. The self-report PedsQL indicated significant improvements in emotional (p=0.02) and social (p=0.03) QoL. As assessed by the QoLiSSY, children reported improvement of social QoL (+0.2 SD, p=0.04), and parents reported improvement of children’s physical (+0.1 SD, p<0.0001), emotional (+0.3 SD, p<0.0001) and social (+0.3 SD, p<0.0001) QoL. Height SDS gains showed moderate positive correlations with QoLISSY self-report score gains (R=0.53, R2=0.28, p<0.001) and QoLISSY parent-report gains (R=0.60, R2=0.41, p<0.00001). Conclusions After one year of GH treatment, children had significant gains in emotional and social QoL, as assessed by a general self-report questionnaire and height-specific parent-report questionnaire.

16 December 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
LBLaura Gabriela González Briceño
Laura Gabriela González Briceño
DKDulanjalee Kariyawasam
Dulanjalee Kariyawasam
DSDinane Samara-Boustani
Dinane Samara-Boustani
EGElisa Giani
Elisa Giani
JBJacques Beltrand
Jacques Beltrand
MPMichel Polak
Michel Polak
Context Endocrine complications are common in pediatric brain tumor patients. Objective We aimed to describe the endocrine follow-up of patients with primary brain tumors. Methods This is a noninterventional observational study based on data collection from medical records of 221 patients followed at a Pediatric Endocrinology Department. Results Median age at diagnosis was 6.7 years (range, 0-15.9), median follow-up 6.7 years (0.3-26.6), 48.9% female. Main tumor types were medulloblastoma (37.6%), craniopharyngioma (29.0%), and glioma (20.4%). By anatomic location, 48% were suprasellar (SS) and 52% non-suprasellar (NSS). Growth hormone deficiency (GHD) prevalence was similar in both groups (SS: 83.0%, NSS: 76.5%; P = 0.338), appearing at median 1.8 years (−0.8 to 12.4) after diagnosis; postradiotherapy GHD appeared median 1.6 years after radiotherapy (0.2-10.7). Hypothyroidism was more prevalent in SS (76.4%), than NSS (33.9%) (P < 0.001), as well as ACTH deficiency (SS: 69.8%, NSS: 6.1%; P < 0.001). Early puberty was similar in SS (16%) and NSS (12.2%). Hypogonadotropic hypogonadism was predominant in SS (63.1%) vs NSS (1.3%), P < 0.001, and postchemotherapy gonadal toxicity in NSS (29.6%) vs SS (2.8%), P < 0.001. Adult height was lower for NSS compared to target height (−1.0 SD, P < 0.0001) and to SS patients (P < 0.0001). Thyroid nodules were found in 13/45 patients (28.8%), including 4 cancers (4.8-11.5 years after radiotherapy). Last follow-up visit BMI was higher in both groups (P = 0.0001), and obesity incidence was higher for SS (46.2%) than NSS (17.4%). Conclusion We found a high incidence of early-onset endocrine disorders. An endocrine consultation and nutritional evaluation should be mandatory for all patients with a brain tumor, especially when the tumor is suprasellar or after hypothalamus/pituitary irradiation.

15 October 2014 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
PDF file
GPGraziella Pinto
Graziella Pinto
VCValérie Cormier-Daire
Valérie Cormier-Daire
MMMartine Le Merrer
Martine Le Merrer
DSDinane Samara-Boustani
Dinane Samara-Boustani
GBGeneviève Baujat
Geneviève Baujat
MPMichel Polak
Michel Polak
Background/Aims: Hypochondroplasia (HCH) is a skeletal dysplasia characterized by disproportionate short stature. The aims of the study are to evaluate efficacy and safety of recombinant human growth hormone (r-hGH) therapy in HCH children, when compared with a historical cohort of untreated HCH children. Methods: Nineteen HCH patients with an initial height standard deviation score (SDS) ≤-2 and a mean age of 9.3 ± 3.1 years were treated with a mean r-hGH dose of 0.053 mg/kg/day over 3 years. Growth charts were derived from the historical cohort (n = 40). Results: Height gain in the treated population was +0.62 ± 0.81 SDS greater than in the general population, and +1.39 ± 0.9 SDS greater than in the historical untreated HCH cohort (mean gain of 7.4 ± 6.6 cm gain). A negative correlation between height gain and age at treatment initiation was reported (p = 0.04). There was no significant difference in response between patients with fibroblast growth factor receptor 3 mutations and those without. No treatment-related serious adverse events were reported. Conclusions: r-hGH treatment is well tolerated and effective in improving growth in HCH patients, particularly when started early. The treatment effect varies greatly and must be evaluated for each patient during treatment to determine the value of continued therapy.

25 April 2024 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
SRSibylle Rovani
Sibylle Rovani
VBVictoria Butler
Victoria Butler
DSDinane Samara-Boustani
Dinane Samara-Boustani
GPGraziella Pinto
Graziella Pinto
LGLaura Gonzalez-Briceno
Laura Gonzalez-Briceno
DKDulanjalee Kariyawasam
Dulanjalee Kariyawasam
Adamantinomatous craniopharyngioma mainly affects children. Excessive weight gain is a major long-term complication. The primary objective of this study was to assess long-term weight changes in children treated for craniopharyngioma. The secondary objectives were to identify risk factors for excessive weight gain and to look for associations with hypothalamic damage by the tumour or treatment. Single-centre retrospective cohort study. Children managed for craniopharyngioma at our centre between 1990 and 2019 were included. The body mass index (BMI) standard deviation scores (SDS) at baseline and at last follow-up were compared. Univariate and multivariate analyses were performed in order to identify variables associated with the long-term BMI-SDS variation. The 108 patients had a mean follow-up of 10.4 years. The mean BMI-SDS increase over time was 2.11 (P < .001) overall, 1.21 (P < .001) in the group without hypothalamic involvement by the tumour, and 1.95 (P < .001) in the group managed using intended hypothalamus-sparing surgery. The absence of hypothalamic involvement by the tumour or treatment was significantly associated with less weight gain (P = .046 and P < .01, respectively). After adjustment, factors associated with a BMI-SDS change greater than 2 were female sex (P = .023), tumour involving the hypothalamus (P = .04), and higher baseline BMI (P < .001). Clinically significant weight gain occurred in nearly all children treated for craniopharyngioma, including those whose hypothalamus was spared by the tumour and intentionally by treatment. However, hypothalamus integrity was associated with less weight gain. Despite hypothalamus-sparing strategies, hypothalamic obesity remains a major concern, indicating a need for novel treatment approaches.

3 November 2019 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
SKSonia Khirani
Sonia Khirani
AAAlessandro Amaddeo
Alessandro Amaddeo
GBGeneviève Baujat
Geneviève Baujat
CMCaroline Michot
Caroline Michot
VCVincent Couloigner
Vincent Couloigner
BFBrigitte Fauroux
Brigitte Fauroux

27 November 2024 in European Journal of Endocrinology
Verified
Journal Article
Closed access
BTBerenice Tulelli
Berenice Tulelli
ABAlix Besançon
Alix Besançon
ASAthanasia Stoupa
Athanasia Stoupa
GPGraziella Pinto
Graziella Pinto
DSDinane Samara-Boustani
Dinane Samara-Boustani
TBThomas Blanc
Thomas Blanc
Objective: Adreno CorticoTropic Hormone (ACTH)-independent Cushing's syndrome (CS) in children is very rare but potentially fatal. In bilateral nodular hyperplasia, synchronous bilateral adrenalectomy (SBA) represents the definitive treatment to correct hypercortisolism. We aim to report the multidisciplinary management of this rare condition. Methods: Presentation, management, and outcomes of all children with ACTH-independent CS who underwent SBA in a tertiary reference center between 1992 and 2022 were retrospectively analyzed. Results: Ten children were included: 6 with McCune–Albright syndrome, 4 with primary pigmented nodular adrenocortical disease (3 with Carney complex). Presentation varied according to age at diagnosis. In infants (n = 7), failure to thrive with anorexia (n = 7), cushingoid facies (n = 7), arterial hypertension (n = 6), hypotonia (n = 5), hyperglycemia (n = 4), liver dysfunction (n = 4), and hypercalcemia with nephrocalcinosis (n = 4) were the main reasons for urgent hospitalization. Prepubertal children (n = 3) presented with linear growth arrest associated with obesity, cushingoid facies, and hirsutism. SBA was indicated in severe neonatal hypercortisolism, or in those that were non-responsive to medical treatment. SBA was performed by robot-assisted laparoscopy (n = 6), laparoscopy (n = 2) or laparotomy (n = 2). One post-operative complication occurred (seroma in the adrenal bed). During follow-up, (median: 4.8 years) no deaths or acute adrenal crisis occurred. Conclusion: Pediatric CS must be referred to a pediatric center with medical and surgical expertise. Shared decision-making regarding SBA must be prompt to allow rapid cure of CS, even if it implies lifelong steroid replacement. This avoids long-term complications of hypercortisolism, particularly cognitive decline. Robot-assisted SBA is feasible and safe, even in infants when performed by an experienced robotic team.